HLA-DP Genetics Point to a New Immune Pathway in Primary Sclerosing Cholangitis
A large immunogenetic study in primary sclerosing cholangitis is drawing a sharper map of how bile duct injury may begin and persist. The central signal is a specific class II HLA haplotype, HLA-DPA102:01~B101:01, which carried a markedly increased risk of PSC in a cohort of 3,408 individuals with the disease and 34,213 controls. The reported odds ratio of 1.99, with a p value of 6.7×10-50, places this haplotype among the strongest genetic associations described in the study.
PSC is defined by progressive bile duct stricturing and chronic cholestatic liver injury that can end in transplantation. Genetics has long pointed to the immune system, especially HLA class II biology, but association alone does not explain how a genotype becomes a tissue-level disease. This work connects the genetic signal to a specific effector population: NKp44+ NK cells, which were enriched in the liver tissue of people with PSC.
A short finding carries much of the weight here: cholangiocytes in PSC appear to display an immune “address label” that can be read by activating NK cells.
NKp44+ NK Cells Accumulate Where Bile Duct Injury Occurs
The tissue analyses move the story beyond statistical association. Using flow cytometry, immunohistochemistry, and immunofluorescence, investigators examined liver tissue as well as intrahepatic and peripheral blood lymphocytes from people with PSC and control individuals. NKp44+ NK cells were enriched in PSC livers, aligning the genetic data with a local immune infiltrate capable of mediating epithelial damage.
At the same time, intrahepatic bile ducts showed higher expression of HLA-DP. In pathophysiologic terms, that matters because HLA-DP is not simply a passive marker of immune activation. It can function as a ligand in this context, creating a direct line of communication between cholangiocytes and NK cells. When a stressed epithelial cell upregulates an HLA molecule that can be sensed by an activating receptor, the result is a plausible route to recurrent injury, amplification of inflammation, and ongoing bile duct remodeling.
The in vitro work strengthens that model. Primary NKp44+ NK cells responded with significantly greater degranulation when exposed to plate-bound HLA-DPA102:01-DPB101:01 than to control HLA-DP molecules. Anti-NKp44 blockade inhibited this response, indicating that the interaction was receptor dependent rather than a nonspecific activation artifact. In clinical terms, the receptor-ligand pair behaves like a trigger, not a bystander.
Cholangiocyte Organoids Reproduce the Interaction at the Epithelial Surface
The organoid experiments give the mechanistic data a second layer of credibility. Human cholangiocyte organoids expressing HLA-DPA102:01-DPB101:01 after IFN-γ exposure bound NKp44-Fc constructs more strongly than unstimulated controls. IFN-γ is relevant here because inflammatory cytokines in diseased liver tissue can increase antigen presentation machinery and shift cholangiocytes into a more immunogenic state. In other words, inflammation may not only follow cholangiocyte damage; it may help convert cholangiocytes into targets that invite further attack.
Even more direct, HLA-DPA102:01-DPB101:01-expressing organoids increased degranulation of NKp44+ NK cells compared with HLA-DPB1-knockout organoids. The knockout comparison narrows the mechanism to the HLA-DP molecule itself. It is the difference between merely observing correlation and reconstructing a functional immune synapse in the laboratory.
For PSC, that distinction is consequential. The disease has often been viewed through the lens of chronic cholangiopathy with incomplete mechanistic resolution, but these data support a model in which genetic susceptibility, cytokine-driven cholangiocyte activation, and innate immune recognition converge at the bile duct epithelium. The liver is not just inflamed in PSC; it may be signaling back to NK cells through a specific HLA-DP configuration that is particularly efficient at engaging NKp44.
Genetic Risk, Epithelial Stress, and a Plausible Therapeutic Target
The association analysis and the functional assays point in the same direction. HLA-DPA102:01~B101:01 emerged as a risk haplotype, and its encoded HLA-DP product interacted with NKp44+ NK cells in a way that increased degranulation. From a bedside perspective, that provides a biologically coherent explanation for why some patients may be genetically primed to sustain progressive bile duct injury after immune activation begins.
The findings also help distinguish PSC from a purely antibody-driven or purely adaptive immune process. NK cells sit at the interface of innate recognition and cytotoxic effector function. When they are recruited to bile ducts that display an activating ligand, they can contribute to epithelial injury without requiring the slower, antigen-specific choreography associated with T cells. That mechanism fits the architectural pattern of PSC, where damage centers on the ducts and proceeds with chronic remodeling.
No therapeutic claim should be stretched beyond the data. The study does not establish a treatment target or show that blocking NKp44 will alter clinical outcomes in PSC. What it does establish is a plausible immune axis with unusually strong coherence across genetics, tissue pathology, and in vitro function. Future work will need to determine whether this interaction marks disease subsets, predicts severity, or can be interrupted safely without impairing host defense.
For now, the most actionable advance is conceptual but concrete: PSC risk is not only associated with HLA class II variation, it is linked to a specific HLA-DP haplotype that can activate NKp44+ NK cells at the cholangiocyte surface. That narrows a broad autoimmune and cholangiopathic syndrome into a receptor-ligand interaction that can be tested, mapped, and potentially targeted in future studies.